Lurbinectedin and irinotecan demonstrate a synergic clinical effect in patients with neuroendocrine carcinomas of gastroenteropatic primary site after chemotherapy failure

Two studies in sarcoma explore the promise of ADCs and theranostics realised in different tumours. 

An early-phase trial shows the efficacy of brigimadlin in dedifferentiated and well-differentiated liposarcomas, but confirmation from phase III results is still awaited

In a post hoc analysis of the DeFi trial, a reduction in symptom burden was reported, with benefits occurring early in treated patients

Uninterrupted imatinib is essential to optimise outcomes in metastatic and high-risk resected GIST

Survival benefits of the radioligand therapy needs to be confirmed in further studies

A study describes an additivity model that can be used to predict the likelihood of success or failure of combination therapies in phase III trials

A study reports evidence of antitumour activity by combining a GDF-15 neutralising antibody with PD-1 inhibition in cancers that are refractory/relapsed to immune checkpoint inhibitors 

Certain immunotherapy combinations that are effective in selected solid tumours may not be effective in lung cancer without targetable genetic alterations.

Analysis from MARIPOSA-2 and FLAURA2 trials show a potential change of treatment paradigm in both first- and second-line settings